NCT03465488View on ClinicalTrials.gov

Validating Egg-based Diagnostics and Molecular Markers for the Spread of Anthelmintic Resistance

NACompletedINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

August 15, 2016

Primary Completion Date

January 1, 2018

Study Completion Date

September 1, 2019

Conditions
Soil-transmitted Helminth Infections
Interventions
DRUG

Albendazole Pill 400mg (GSK)

One single dose of 400mg Albendazole is provided at baseline.

Trial Locations (4)

Unknown

Fiocruz - Research institute of Renê Rachou, Belo Horizonte

Jimma University, Jimma

National Institute of Public Health, Vientiane

The Public Health Laboratory - Ivo de Carneri (PHL-IdC), Chake Chake

All Listed Sponsors
collaborator

Swiss Tropical & Public Health Institute

OTHER

lead

University Ghent

OTHER

NCT03465488 - Validating Egg-based Diagnostics and Molecular Markers for the Spread of Anthelmintic Resistance | Biotech Hunter | Biotech Hunter